Scotiabank initiated coverage on EyePoint Pharmaceuticals
$EYPT
Biotechnology: Laboratory Analytical Instruments
Industrials
Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2025 | $33.00 | Buy | Citigroup |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/28/2024 | $15.00 | Buy | Jefferies |
| 1/22/2024 | $35.00 | Overweight | JP Morgan |
| 11/2/2023 | $20.00 | Buy | Mizuho |
| 4/21/2023 | $33.00 | Outperform | Robert W. Baird |
| 7/7/2022 | $21.00 | Buy | Chardan Capital Markets |
| 11/15/2021 | $15.00 → $24.00 | Buy | HC Wainwright & Co. |
Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00
Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform
Jefferies initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $15.00
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
– Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in 2024 – – Positive twelve-month data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD continue to demonstrate favorable safety and efficacy – – Phase 2 VERONA trial of DURAVYU in DME fully enrolled with topline data anticipated in Q1 2025 – – $280.2 million of cash and investments on June 30, 2024, with cash runway through Phase 3 wet AMD topline data for DURAVYU in 2026 – WATERTOWN, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative thera
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained six-month maintenance therapy – – Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled – – EyePoint to webcast its R&D Day event today at 8:00 a.m. ET – WATERTOWN, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET. The R&D Day will feature presentations and a roundtable discussion from key opinion leader (KOL) guest speakers Carl D. Regillo, M.D., FACS, Professor of Ophthalmology at Thomas Jefferson University, Chief of Retina Service at Wills Eye Hospital, Founder of Wills Eye Clinical Retina Research Unit in Philadelphia, and Partner at
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
SCHEDULE 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
3 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET. A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com. About EyePoint Pharmaceuticals EyePoint (NASDAQ:EYPT) is a clinical-stage biophar
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025. The grants were approved by the Compensation Committee
– Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2 VERONA clinical trial of DURAVYU in DME expected in 1Q 2025 – – Appointed renowned retina specialist and industry leader Reginald J. Sanders, M.D., FASRS to Board of Directors – – Cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – – Presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT – WATERTOWN, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San
WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists